213 related articles for article (PubMed ID: 28323987)
1. Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function.
Zaheer S; de Boer IH; Allison M; Brown JM; Psaty BM; Robinson-Cohen C; Michos ED; Ix JH; Kestenbaum B; Siscovick D; Vaidya A
J Clin Endocrinol Metab; 2017 Apr; 102(4):1387-1395. PubMed ID: 28323987
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
[TBL] [Abstract][Full Text] [Related]
3. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
[TBL] [Abstract][Full Text] [Related]
5. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
[TBL] [Abstract][Full Text] [Related]
6. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
[TBL] [Abstract][Full Text] [Related]
7. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals.
Mirza MA; Alsiö J; Hammarstedt A; Erben RG; Michaëlsson K; Tivesten A; Marsell R; Orwoll E; Karlsson MK; Ljunggren O; Mellström D; Lind L; Ohlsson C; Larsson TE
Arterioscler Thromb Vasc Biol; 2011 Jan; 31(1):219-27. PubMed ID: 20966399
[TBL] [Abstract][Full Text] [Related]
8. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
Kanda E; Yoshida M; Sasaki S
BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
[TBL] [Abstract][Full Text] [Related]
10. Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.
Isakova T; Cai X; Lee J; Katz R; Cauley JA; Fried LF; Hoofnagle AN; Satterfield S; Harris TB; Shlipak MG; Sarnak MJ; Ix JH;
J Bone Miner Res; 2016 Apr; 31(4):742-8. PubMed ID: 26590361
[TBL] [Abstract][Full Text] [Related]
11. Comparison between Different Measures of Body Fat with Kidney Function Decline and Incident CKD.
Madero M; Katz R; Murphy R; Newman A; Patel K; Ix J; Peralta C; Satterfield S; Fried L; Shlipak M; Sarnak M
Clin J Am Soc Nephrol; 2017 Jun; 12(6):893-903. PubMed ID: 28522656
[TBL] [Abstract][Full Text] [Related]
12. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
[TBL] [Abstract][Full Text] [Related]
13. Role of adiponectin in the relationship between visceral adiposity and fibroblast growth factor 23 in non-diabetic men with normal kidney function.
Natsuki Y; Morioka T; Fukumoto S; Kakutani Y; Yamazaki Y; Ochi A; Kurajoh M; Mori K; Shoji T; Imanishi Y; Inaba M; Emoto M
Endocr J; 2022 Feb; 69(2):121-129. PubMed ID: 34497173
[TBL] [Abstract][Full Text] [Related]
14. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
15. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men.
Marsell R; Grundberg E; Krajisnik T; Mallmin H; Karlsson M; Mellström D; Orwoll E; Ohlsson C; Jonsson KB; Ljunggren O; Larsson TE
Eur J Endocrinol; 2008 Jan; 158(1):125-9. PubMed ID: 18166826
[TBL] [Abstract][Full Text] [Related]
17. Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus.
Freedman BI; Divers J; Russell GB; Palmer ND; Bowden DW; Carr JJ; Wagenknecht LE; Hightower RC; Xu J; Smith SC; Langefeld CD; Hruska KA; Register TC
Am J Nephrol; 2015; 42(6):391-401. PubMed ID: 26693712
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study.
Ishigami J; Jaar BG; Rebholz CM; Grams ME; Michos ED; Wolf M; Kovesdy CP; Uchida S; Coresh J; Lutsey PL; Matsushita K
J Clin Endocrinol Metab; 2017 Dec; 102(12):4648-4657. PubMed ID: 29029099
[TBL] [Abstract][Full Text] [Related]
19. FGF23, Frailty, and Falls in SPRINT.
Jovanovich A; Ginsberg C; You Z; Katz R; Ambrosius WT; Berlowitz D; Cheung AK; Cho M; Lee AK; Punzi H; Rehman S; Roumie C; Supiano MA; Wright CB; Shlipak M; Ix JH; Chonchol M
J Am Geriatr Soc; 2021 Feb; 69(2):467-473. PubMed ID: 33289072
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study.
Wright CB; Shah NH; Mendez AJ; DeRosa JT; Yoshita M; Elkind MS; Sacco RL; DeCarli C; Rundek T; Silverberg S; Dong C; Wolf M
Stroke; 2016 Apr; 47(4):923-8. PubMed ID: 26956260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
